Oleorresina de duas espécies de Copaifera: isolamento e identificação estrutural de diterpenos e desenvolvimento e validação de método analítico por CLAE-DAD

• Autor(a) principal: Souza, Ariana Borges
• Data de Publicação: 2015
• Tipo de documento: Tese
• Idioma: por
• Título da fonte: Repositório do Centro Universitário Braz Cubas
• Texto Completo: https://repositorio.cruzeirodosul.edu.br/handle/123456789/391
• topic: Copaifera; C. langsdorffii; C. oblongifolia; diterpenos; CLAE-DAD; validação; ácido ent-7-epoxi-13-labdeno-15-óico; CNPQ::CIENCIAS EXATAS E DA TERRA

The Copaifera oleoresins (Fabaceae) are usefull in folk medicine for the treatment of several human diseases. The literature describes some pharmacological activities of these natural products, however, very few is known about which compounds are responsible for such activities. Also, it is not known if these commercial oleoresins are obtained from authentic species, mixed especies or even if it was adulterated. For this reason, there is a need to develop new analytical methods to verify the authenticity of commercial oleoresins and the authentic species. In this sense, the aim of such study was to investigate the phytochemical profile of two Copaifera species, C. langsdorffii found along all Brazilian territory, and C. oblongifolia which doesn’t have commercial value but uninvestigated under the chemical and pharmacological view. In addition, this work aimed yet the development and validation of analytical methods for both Copaifera species, using High Performance Liquid Chromatography to determine the concentration of some reference standards. The isolated metabolites from C. langsdorffii (caryophyllene oxide; ent-copalic acid; ent-kaurenoic acid; ent-3β-acetoxy-labda-8(17),13-dien-15- oic acid; agathic acid and 3β-hydroxy-ent-copalic acid) and from C. oblongifolia (coleonic acid, hardwickiic acid and the new diterpene the ent-7-epoxy-13-labden15-oic acid) were identified by 1H and 13C Nuclear Magnetic Resonance. The analytical studies allowed the development of robust and reliable methods and that attend the parameters established by ANVISA (RE nº899/2003).